secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092279
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M
---------------------------------------------------------------------

- Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.
- US composition of matter patent issued for obicetrapib, extending IP protection to July 2043.
- Cash $430.7M as of June 30, 2024 (up from $340.5M at Dec 31, 2023).
- Q2 net loss $39.0M ($0.41 diluted EPS) vs $38.3M ($0.47) year ago; revenue $2.3M (vs $1.7M).
- Topline data for Phase 3 BROADWAY expected Q4 2024; Phase 3 TANDEM enrollment completed, topline Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/0000950170-24-092279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/nams-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer